ZA200209473B - Pharmaceutical composition. - Google Patents

Pharmaceutical composition.

Info

Publication number
ZA200209473B
ZA200209473B ZA200209473A ZA200209473A ZA200209473B ZA 200209473 B ZA200209473 B ZA 200209473B ZA 200209473 A ZA200209473 A ZA 200209473A ZA 200209473 A ZA200209473 A ZA 200209473A ZA 200209473 B ZA200209473 B ZA 200209473B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
masked
decomposing
excipients
lipid
Prior art date
Application number
ZA200209473A
Other languages
English (en)
Inventor
Fernandez Matilde Ibanez
Emilio Sanz Garriz
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA200209473B publication Critical patent/ZA200209473B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
ZA200209473A 2001-11-23 2002-11-21 Pharmaceutical composition. ZA200209473B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23

Publications (1)

Publication Number Publication Date
ZA200209473B true ZA200209473B (en) 2003-06-10

Family

ID=8183502

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200209473A ZA200209473B (en) 2001-11-23 2002-11-21 Pharmaceutical composition.

Country Status (34)

Country Link
US (1) US20030161888A1 (it)
EP (1) EP1446126B1 (it)
JP (1) JP3497503B2 (it)
KR (1) KR100979328B1 (it)
CN (1) CN1297274C (it)
AT (1) ATE473006T1 (it)
AU (2) AU2002302147B2 (it)
BE (2) BE1015217A5 (it)
BR (1) BR0204767A (it)
CA (1) CA2408198C (it)
CH (1) CH693982A5 (it)
CO (1) CO5580783A2 (it)
CY (1) CY1110778T1 (it)
CZ (1) CZ12993U1 (it)
DE (3) DE60236952D1 (it)
DK (1) DK1446126T3 (it)
ES (2) ES2201932B2 (it)
FR (1) FR2832635B1 (it)
GB (1) GB2383536B (it)
GR (1) GR1004522B (it)
HR (2) HRP20020924A2 (it)
HU (1) HUP0204026A3 (it)
IL (2) IL161972A0 (it)
IT (1) ITMI20022470A1 (it)
MX (1) MXPA02011561A (it)
NO (1) NO335273B1 (it)
NZ (1) NZ533092A (it)
PL (1) PL205325B1 (it)
PT (1) PT1446126E (it)
RU (1) RU2241460C2 (it)
SI (1) SI1446126T1 (it)
TR (1) TR200202559A2 (it)
WO (1) WO2003043638A1 (it)
ZA (1) ZA200209473B (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) * 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术(石家庄)有限公司 一种微囊化头孢呋辛酯的药物组合物
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
WO2011085181A1 (en) * 2010-01-08 2011-07-14 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
WO2011139254A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical formulations compising cefuroxime axetil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
EP2741750A1 (en) * 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
WO2013066616A1 (en) 2011-10-31 2013-05-10 Glaxo Wellcome Manufacturing Pte Ltd Pazopanib formulation
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
CA1094545A (en) * 1976-02-16 1981-01-27 Michael Gregson Cephalosporin antibiotics
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
AU5681294A (en) * 1992-11-30 1994-06-22 Kv Pharmaceutical Company Tastemasked pharmaceutical materials
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
ES2565163T3 (es) * 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
AU2002302147B2 (en) 2005-01-20
DE20218068U1 (de) 2003-03-27
PL205325B1 (pl) 2010-04-30
RU2241460C2 (ru) 2004-12-10
JP3497503B2 (ja) 2004-02-16
CH693982A5 (de) 2004-05-28
BR0204767A (pt) 2003-09-16
HUP0204026A2 (hu) 2003-08-28
BE1014078A6 (fr) 2003-03-04
EP1446126A1 (en) 2004-08-18
JP2003160493A (ja) 2003-06-03
CO5580783A2 (es) 2005-11-30
IL161972A (en) 2009-06-15
AU2002338950A1 (en) 2003-06-10
HRP20020924A2 (en) 2003-10-31
CA2408198A1 (en) 2003-02-02
CN1421206A (zh) 2003-06-04
CZ12993U1 (cs) 2003-02-10
CY1110778T1 (el) 2015-06-10
ATE473006T1 (de) 2010-07-15
GB0227215D0 (en) 2002-12-24
GB2383536A (en) 2003-07-02
NZ533092A (en) 2006-02-24
NO20042620L (no) 2004-06-22
PL357259A1 (en) 2003-06-02
GR1004522B (el) 2004-04-06
CA2408198C (en) 2004-03-09
PT1446126E (pt) 2010-09-24
ITMI20022470A1 (it) 2003-05-24
DE10254412A1 (de) 2003-06-12
KR100979328B1 (ko) 2010-08-31
US20030161888A1 (en) 2003-08-28
WO2003043638A1 (en) 2003-05-30
ES2201932B2 (es) 2005-03-16
EP1446126B1 (en) 2010-07-07
KR20050044590A (ko) 2005-05-12
IL161972A0 (en) 2005-11-20
HU0204026D0 (en) 2003-01-28
MXPA02011561A (es) 2005-07-13
SI1446126T1 (sl) 2010-10-29
BE1015217A5 (it) 2004-11-09
NO335273B1 (no) 2014-11-03
HRP20020923A2 (en) 2003-10-31
ES2347536T3 (es) 2010-11-02
TR200202559A2 (tr) 2003-06-23
FR2832635A1 (fr) 2003-05-30
CN1297274C (zh) 2007-01-31
DE60236952D1 (de) 2010-08-19
GR20020100506A (el) 2003-07-16
GB2383536B (en) 2003-11-19
ES2201932A1 (es) 2004-03-16
HUP0204026A3 (en) 2004-09-28
FR2832635B1 (fr) 2006-04-21
DK1446126T3 (da) 2010-10-11

Similar Documents

Publication Publication Date Title
GB2383536B (en) Pharmaceutical Composition
BR9912979B1 (pt) composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
HK1035142A1 (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
MY103525A (en) Pharmaceutical composition comprising cefuroxime axetil
AU2003223989A1 (en) System for orally administering active substances, vitamins and/or foodstuffs
CA2242114A1 (en) Nutritional supplement for the treatment and prevention of excessive intestinal permeability
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
WO2002047607A3 (en) Process for the preparation of a fast dissolving dosage form
HK1034674A1 (en) Orally administrable solid ribavirin dosage forms and process for making them.
WO2005007137A8 (de) Ambroxolhaltige tabletten
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
WO2003061728A3 (en) Oral administration of interferon-tau
WO2002017894A3 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
AU5634500A (en) Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis
GEP20063821B (en) Orodispersible pharmaceutical composition comprising perindopril
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
AU4929400A (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
AU4655199A (en) Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
AU2003256157A1 (en) Oral dosage forms of water insoluble drugs and methods of making the same
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
GB9910773D0 (en) Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract
WO1998036732A3 (de) Kombinationspräparat für oral applizierbare antibiotika
WO2001062263A3 (en) Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome
Yim et al. The Effects of Dietary Counceling and Drug Treatment of the Serum Lipid Levels in Hyperlipidemic Patients
RU2002120354A (ru) Биологически активная добавка "мумивит с витамином "с"